Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27878089 | 0.84 | CYP19A1 (0.53) | CYP19A1KIF11LMNACYP1A2CYP3A4 | |
| SCHEMBL29226475 | 0.82 | CYP19A1 (0.51) | CYP19A1GPR55LMNACYP1A2CYP3A4 | |
| SCHEMBL5459597 | 0.82 | GPR55 (0.49) | CYP19A1GPR55KIF11LMNACYP1A2 | |
| SCHEMBL29226478 | 0.82 | CYP19A1 (0.51) | CYP19A1GPR55LMNACYP1A2CYP3A4 | |
| SCHEMBL30927967 | 0.82 | CYP19A1 (0.51) | CYP19A1GPR55LMNACYP1A2CYP3A4 | |
| SCHEMBL2082074 | 0.81 | CYP19A1 (0.77) | CYP19A1CYP3A4 | |
| SCHEMBL11626306 | 0.80 | CYP19A1 (0.50) | CYP19A1GPR55KIF11LMNACYP1A2 | |
| SCHEMBL11630004 | 0.80 | CYP19A1 (0.50) | CYP19A1GPR55LMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL11627727 | 0.78 | CYP19A1 (0.49) | CYP19A1GPR55KIF11LMNACYP1A2 | |
| SCHEMBL19865034 | 0.78 | CYP19A1 (0.51) | CYP19A1GPR55KIF11LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | CYP19A1 2304/4885GPR55 227/4885KIF11 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.